Provided is a method of preparing a medical hydrogel derived from a chitosan derivative containing aldonic acid bound by dehydration condensation to an amino group of a glucosamine unit of chitosan, the method including placing an aqueous solution containing the chitosan derivative in a mold having a predetermined shape, and then subjecting the aqueous solution to high-pressure steam sterilization, to obtain a sterile medical hydrogel having the predetermined shape. The resulting medical hydrogel can be used as a wound dressing for use in the treatment of wound surfaces of cut wounds, lacerated wounds, contused wounds, burns, bedsores, and the like.
A temperature control device (1) has a heat diffusion plate (10) that comprises: a housing (20) that has a sealed internal space (IS) and is formed from a material that includes any of a ceramic, a ceramic composite material, and an inorganic substance that is not a metal; and a working fluid (21) that is sealed in the internal space (IS) and circulates through the internal space (IS) along the surface direction of a first surface (S1) while repeatedly being vaporized by reception of heat and condensed by release of heat. To make the heat uniformization time from input or absorption of heat into the heat diffusion plate (10) until the temperature of the first surface (S1) is uniform shorter than the heat uniformization time of a hollow plate of the same shape, size, and substance as the heat diffusion plate (10), the Biot number of the heat diffusion plate (10) is smaller than the Biot number of the hollow plate of the same shape, size, and substance as the heat diffusion plate (10), and the temperature diffusion coefficient of the heat diffusion plate (10) is greater than the heat diffusion coefficient of the hollow plate of the same shape, size, and substance as the heat diffusion plate (10).
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
A bubble formation device includes a first porous body (11) and a second porous body (12). The first porous body (11) has an array of first through-holes (11a). Gas is injected from ends of the first through-holes (11a) at a first surface (S1) to generate fine bubbles (B) at ends thereof at a second surface (S2) that is in contact with a liquid (L). The second porous body (12) has an array of second through-holes (12a) through which the fine bubbles (B) and the liquid (L) can pass, and is disposed in the liquid (L) so as to deform the fine bubbles (B) growing from the ends of the first through-holes (11a) at the first surface (S1). The second porous body (12) is disposed with a gap (E), through which the fine bubbles (B) and the liquid (L) can pass, with respect to the first porous body (11) such that the direction of the second through-holes (12a) is the same as that of the first through-holes (11a).
B01F 25/452 - Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces
B01F 23/2373 - Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media for obtaining fine bubbles, i.e. bubbles with a size below 100 µm
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japan)
Inventor
Kohara Kyoko
Morita Kouichi
Yasutomi Yasuhiro
Ishii Koji
Abstract
This dengue virus vaccine contains a recombinant vaccinia virus having both DNA that encodes a region other than NS1 in a non-structural protein of a dengue virus and a promoter that regulates the expression of a region other than NS1. The dengue virus vaccine is administered twice or more to a patient to be vaccinated.
A detection method performed by a detection device according to the present invention detects that an anchor screw embedded in an alveolar bone has come into contact with or approached a tooth root. It is determined whether or not an anchor screw has come into contact with or into proximity to a tooth root on the basis of a decrease, with respect to first mobility of one or two teeth which has been measured before the anchor screw is embedded into an alveolar bone, in second mobility of the teeth that is measured after a start of the embedding of the anchor screw into the alveolar bone (steps S1-S6).
METHOD FOR PRODUCING MACROPHAGES, DIFFERENTIATION INDUCING AGENT, DIFFERENTIATION INDUCTION KIT, METHOD FOR CULTURING MACROPHAGES, AGENT FOR PROMOTING MACROPHAGE PROPAGATION, KIT FOR PROMOTING MACROPHAGE PROLIFERATION, METHOD FOR MACROPHAGE PROLIFERATION, AND MACROPHAGES
This hydrogel for body cavity injury treatment is derived from a chitosan derivative in which an aldonic acid is bonded by dehydration condensation to an amino group of a glucosamine unit of chitosan. The hydrogel for body cavity injury treatment is granular, the hydrogen being injected into a body cavity by an injector and being used for wound treatment in a body cavity. This body cavity injury treatment kit comprises an injector, a tube connected to the injector, and a granular hydrogel for body cavity injury treatment that is filled into the injector. The hydrogel for body cavity injury treatment is derived from a chitosan derivative in which an aldonic acid is bonded by dehydration condensation to an amino group of a glucosamine unit of chitosan.
This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
The present invention provides a complex for bone regeneration or augmentation, the complex comprising a bone substitute material covered with a layered cell sheet containing osteogenic cells.
A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
10.
METHOD FOR PRODUCING HUMAN MACROPHAGE, DIFFERENTIATION-INDUCING AGENT, DIFFERENTIATION-INDUCING KIT, METHOD FOR INDUCING DIFFERENTIATION OF HUMAN MACROPHAGE, PROLIFERATION-PROMOTING AGENT FOR HUMAN MACROPHAGE, KIT FOR PROMOTING PROLIFERATION OF HUMAN MACROPHAGE, METHOD FOR PROLIFERATING HUMAN MACROPHAGE, AND HUMAN MACROPHAGE
This method for producing human macrophages includes a culturing step for culturing human hematopoietic progenitor cells in the presence of TREM2 signal activating agent, with a culture medium substantially free of any of a macrophage colony stimulating factor and free of a granulocyte macrophage colony stimulating factor.
A crosslinking agent for a protein or a peptide is represented by the following formula (I). In the formula, A is a hydrogen atom, a C1 to 6 alkyl group optionally substituted with a phenyl group or a halogen atom, or a phenyl group.
A crosslinking agent for a protein or a peptide is represented by the following formula (I). In the formula, A is a hydrogen atom, a C1 to 6 alkyl group optionally substituted with a phenyl group or a halogen atom, or a phenyl group.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
12.
CO2 SEPARATION COMPOSITE MEMBRANE AND METHOD FOR PRODUCING SAME
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Kaneko Yoshiro
Nakano Yumi
Taniyama Kakeru
Yuasa Kayoko
Fujikawa Shigenori
Abstract
222 separation composite membrane, the method comprising: a step for forming a first separation layer including a polysiloxane-containing layer; and a step for forming a second separation layer selected from the group consisting of a polyethylene glycol-containing layer and an imidazolium salt-type ionic liquid component-containing layer on the first separation layer. In the step for forming the second separation layer, a polyethylene glycol-containing layer or an imidazolium salt-type ionic liquid component-containing layer is chemically bonded to the polysiloxane-containing layer to form the second separation layer.
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.
spcc [mm] is the permissible bending deformation amount for the housing (50); E [N/mm2] is the longitudinal elastic modulus of the housing (50); I [mm2] is the secondary cross-sectional moment of inertia of the housing (50); and w [N/mm] is a uniformly distributed load that is applied per unit length to the housing (50) by an internal pressure generated in the internal space (20) or an external pressure.
F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
H01L 23/427 - Cooling by change of state, e.g. use of heat pipes
H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating
15.
CAPSULE PRODUCTION METHOD AND CAPSULE PRODUCTION DEVICE
A tubular body (111) has a shape of tube surrounding a virtual center line (VL). A guide groove (112) that is helical about the virtual center line (VL) is provided in the inner surface of the tubular body (111). A rotation device (120) rotates the tubular body (111) around the virtual center line (VL). A dropping device (130) drops, on the inner surface of the tubular body (111), an inclusion substance and a wall material precursor liquid that is a precursor of a wall material covering the inclusion substance. A liquid droplet dropped by the dropping device (130) rolls in the guide groove (112) of the tubular body (111), the tubular body (111) being rotated by the rotation device (120).
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
16.
REPLICON DNA, CLONING VECTOR, SCREENING KIT, SCREENING METHOD, ANTI-NOBECOVIRUS AGENT, BETA-CORONAVIRUS PROLIFERATION INHIBITOR, PAN BETA-CORONAVIRUS INHIBITOR, VIRUS PROLIFERATION INHIBITOR, HEPATITIS C VIRUS PROLIFERATION INHIBITOR, AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR VIRAL INFECTIOUS DISEASE
This replicon DNA includes: a CMV promoter sequence that functions in vertebrate cells; a non-structural region that is positioned on the 3' side from the CMV promoter sequence and includes non-structural protein genes 1a and 1b from a nobecovirus; and the N gene from the nobecovirus, which is positioned on the 3' side from the non-structural region.
This film deposition method is for depositing a polymer film on a surface of a substrate in a solution. The method has: a step of immersing the substrate into a first solution containing a polymerization initiator; a step of bonding a polymerization initiation group to the surface of the substrate by applying ultrasonic waves to the first solution; a step of immersing the substrate having the polymerization initiation group bonded to the surface into a second solution containing a polymerizable monomer; and a step of growing the polymer on the surface of the substrate by a polymerization reaction of the polymerizable monomer, starting from the polymerization initiation group.
This method for producing a radiolabeled antibody comprises a conjugating step for reacting a compound represented by formula (1): P1-S-Y-B or a salt thereof with IgG. In formula (1), P1 represents a labeled moiety that is labeled with a radioisotope or a labeling moiety that is capable of being labeled with a radioisotope. S represents a spacer. Y indicates a reaction moiety that reacts with the IgG. B indicates an antibody-binding moiety comprising an IgG-binding peptide capable of binding specifically to an Fc region in the IgG. Y in formula (1) has a group represented by formula I. R1represents a substituent which makes the pKa value of R1-H to 4 to 14. R2is bound to S in formula (1). R3is bonded to B in formula (1). R4 represents H or a substituted or unsubstituted alkyl group having 1 to 8 carbon atoms.
The fine hollow particle of the present invention is a fine hollow particle composed of a resin film comprising a melamine-based resin, in which the resin film is composed of a plurality of small piece-shaped portions and a bonding portion for bonding the plurality of small piece-shaped portions. According to the present invention, it is possible to provide stable fine hollow particles having excellent solvent resistance and heat resistance, good dispersibility, and a large particle diameter.
An intermolecular interaction analysis device (1) comprises: a molecular location unit (12) that determines the location of a molecule B, indicated by three-dimensional structure data (22) of the molecule B, with respect to the position of a molecule A, indicated by three-dimensional structure data (21) of the molecule A; a contact surface defining unit (13) that defines, as a contact surface, a surface on which an electron density of the molecule A computed from the three-dimensional structure data (21) of the molecule A and an electron density of the molecule B computed from the three-dimensional structure data (22) of the molecule B are equal to each other; and an evaluation unit (14) that evaluates an attractive interaction between the molecule A and the molecule B on the basis of electrostatic complementarity between the molecule A and the molecule B on the contact surface that is quantitatively determined from the electrostatic potential of the molecule A computed from the three-dimensional structure data (21) of the molecule A and the electrostatic potential of the molecule B computed from the three-dimensional structure data (22) of the molecule B.
To provide an adhesive capable of realizing adhesion excellent in shear strength and impact resistance, a polysiloxane composition usable as a component contained in the adhesive, and respective methods for producing the adhesive and the polysiloxane composition. The polysiloxane composition is a copolymer of an adhesive monomer unit A including an organosiloxane unit containing a substituent RA2 containing a catechol group, and a flexible monomer unit B including an organosiloxane unit containing no catechol group.
C08G 77/26 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen nitrogen-containing groups
C09J 183/08 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Yamato, Kenta
Miyata, Takeshi
Kusakabe, Takahiro
Lee, Jae Man
Masuda, Akitsu
Abstract
A method of easily producing an immunogenic pupa for oral administration and a pupa for oral administration produced by the method are provided. The method is a method of producing a pupa for oral administration, including a step of infecting a larva or pupa of an insect capable of being baculovirus-infected with a recombinant baculovirus having DNA encoding an antigen protein introduced therein and freeze-drying a pupa having pupated from the infected larva or the infected pupa.
A temperature control device (1) comprises: a heat diffusion plate (10) that is a member provided with a first surface (S1) facing a controlled object (CO) and a second surface (S2) parallel to the first surface (S1) and facing the opposite direction therefrom, and in which heat is diffused in the surface direction of the first surface (S1); and a heat source (11) that is thermally bonded with the heat diffusion plate (10) at the second surface (S2) and heats or absorbs heat from the heat diffusion plate (10). In this design method, the sizes of the heat diffusion plate (10) and the heat source (11) and the thermal conductivity and overall heat transfer coefficient of the heat diffusion plate (10) are determined on the basis of a computation formula indicating the relationship between the ambient temperature around the controlled object (CO), a target temperature for the controlled object (CO), the amount of heat input to the heat diffusion plate (10) from the heat source (11), the sizes of the heat diffusion plate (10) and the heat source (11), the thermal conductivity and the overall heat transfer coefficient of the heat diffusion plate (10), and variation in temperature on the first surface (S1) so that the difference between the maximum temperature and the minimum temperature of a part of the first surface (S1) in contact with the controlled object (CO) when the ambient temperature, the target temperature, and the input amount of heat serve as given design conditions falls within a permissible value range for in-plane temperature variation in the controlled object (CO).
H01L 21/324 - Thermal treatment for modifying the properties of semiconductor bodies, e.g. annealing, sintering
F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
The present invention provides a novel therapeutic means that is relatively low invasive and capable of exerting a desired therapeutic effect on diabetes including T1D. Specifically, an agent for protecting and/or regenerating a pancreatic β cell in a mammal with diabetes is provided, which contains a nucleic acid encoding a heparin-binding epidermal growth factor-like growth factor (HB-EGF), wherein the agent is systemically administered. The aforementioned preparation in combination with a nucleic acid encoding hepatocyte growth factor (HGF) is also provided.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
27.
CELL-TO-CELL HTLV-1 INFECTION INHIBITOR, REMEDY FOR HTLV-1 INFECTION, REMEDY FOR HTLV-1-ASSOCIATED MYELOPATHY (HAM/TSP)
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
A61P 25/00 - Drugs for disorders of the nervous system
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
28.
ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE
The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
Inventor
Kono Hiroshi
Sugiura Yuki
Abstract
The zirconia ceramic according to an embodiment has a crystal structure comprising zirconium, silver, and oxygen ions. The method for producing a zirconia ceramic according to an embodiment includes a sediment formation step (S1) and a firing step (S3). In the sediment formation step (S1), a zirconium compound and a silver compound are mixed in a solution or suspension state and a precipitant is then added to the solution or suspension, thereby obtaining a sediment comprising zirconia derived from the zirconium compound and silver derived from the silver compound. In the firing step (S3), a firing powder obtained by drying the sediment is fired to obtain a zirconia ceramic with which silver ions have combined.
The present invention is a cyclic organopolysiloxane characterized by being represented by general formula (1). Thus, provided are: a cyclic organopolysiloxane that has excellent adhesiveness to metal and resin and that provides an adhesive auxiliary agent capable of stably imparting adhesiveness even when exposed to a high-temperature, high-humidity environment for a long period of time; a silicone composition that contains the cyclic organopolysiloxane; an adhesive auxiliary agent; and an adhesive. (In the formula, each R1 is independently an alkylene group having 1-8 carbon atoms, m is an integer of 1-3, n is an integer of 1-3, and the sum of m and n is 4-6. The siloxane units may be arranged in any order.)
The present invention is a cyclic organopolysiloxane characterized by being represented by general formula (1). Through this feature, provided are: a cyclic organopolysiloxane that is an adhesion promoter excellent in adhesion to a metal and a resin, in particular, to a polycarbonate resin and that is capable of safely imparting adhesion even when exposed under a high temperature and highly humid environment for a long period of time; and a silicone compound and an adhesive containing the same. (In the formula, R1is independently an alkyl group having 1 to 4 carbon atoms, R2 is independently an alkylene group having 1 to 8 carbon atoms, m is an integer of 1 to 3, n is an integer of 1 to 3, and the sum of m and n is 4 to 6. The sequence order of siloxane units is arbitrary.)
A nozzle (100) for bubble formation demarcates a gas channel (110). The gas channel (110) ejects bubbles (FB) of a gas introduced through one end (110a), from the other end (110b) into a static liquid (LQ). When the length of the gas channel (110) from the one end (110a) to the other end (110b) is expressed by L [m], the equivalent diameter of the gas channel (110) is expressed by D [m], and the dynamic viscosity of the gas is expressed by ν [m2/s], then the nozzle (100) for bubble formation satisfies the relationship L>24.0×(D2/4ν).
B01F 23/231 - Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids by bubbling
B01F 25/21 - Jet mixers, i.e. mixers using high-speed fluid streams with submerged injectors, e.g. nozzles, for injecting high-pressure jets into a large volume or into mixing chambers
34.
DATA DISTRIBUTION SYSTEM, DATA DISTRIBUTION DEVICE, RECORDING MEDIUM, AND DATA DISTRIBUTION METHOD
A data distribution device distributes a plurality of sets of data to a user one set of data at a time intermittently at intervals. Every time derived data obtained using the data are generated by the user, a registration device for user registers derived data generation history information indicating that the derived data are generated in a history management database. A derived data generation history information monitor examines whether or not derived data generation history information is registered in the history management database at a predetermined timing and, when no derived data generation history information is registered, suspends subsequent distribution of the data from the data distributor to the user.
An intermolecular interaction analysis device (1) comprises: a contact surface defining unit (30) that defines, as a contact surface, a surface where a partial electron density of a molecule A calculated by an electron density calculation unit (10) and a partial electron density of a molecule B calculated by an electron density calculation unit (20) become equal; an electrostatic potential calculation unit (40) that uses an FMO method to calculate a partial electrostatic potential of the molecule A at the contact surface while excluding the contribution of a charged amino acid residue which corresponds to the electric charge of the molecule A; and an electrostatic potential calculation unit (50) that uses an FMO method to calculate a partial electrostatic potential of the molecule B at the contact surface while excluding the contribution of a charged amino acid residue which corresponds to the electric charge of the molecule B.
NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY (Japan)
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japan)
KAGOSHIMA UNIVERSITY (Japan)
BEACLE, INC. (Japan)
TOKO YAKUHIN KOGYO CO., LTD. (Japan)
Inventor
Hiasa, Yoichi
Yoshida, Osamu
Kohara, Michinori
Kohara, Kyoko
Goh, Yasumasa
Oda, Yasunori
Kamishita, Taizou
Miyazaki, Takashi
Abstract
The present invention addresses the problem of providing a vaccine composition for nasal administration that is usable for preventing and treating hepatitis B, and a nasal administration system of the vaccine. Provided is a hepatitis B vaccine composition that comprises: (i) virus-like particles containing hepatitis B surface L antigen proteins (HBs-L antigen proteins) of two or more genotypes selected from the group consisting of types A, B, C and D, and a hepatitis B nucleocapsid antigen (HBc antigen) protein; and (ii) a base material containing a carboxyvinyl polymer having been treated by externally applying a shear force. Also provided is a nasal administration system of the hepatitis B vaccine, said system comprising the composition filled into a sprayable device equipped with a nasal spray nozzle.
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japan)
KAGOSHIMA UNIVERSITY (Japan)
NATIONAL HOSPITAL ORGANIZATION (Japan)
Inventor
Kohara Michinori
Kohara Kyoko
Yatsuhashi Hiroshi
Abstract
The present invention provides: a biomarker for detecting liver disease at high accuracy and noninvasively or minimally invasively; a kit, a method, and a program for detecting liver disease at high accuracy and noninvasively or minimally invasively using the biomarker; a data processing method for detecting liver disease at high accuracy using the liver disease noninvasive marker; and a data processing device for use in the data processing. More specifically, provided is a biomarker selected from the group consisting of SEQ ID NOS: 1-125. Also provided is a detection kit for liver disease that includes a nucleic acid capable of binding specifically with a specific miRNA. Additionally provided are: a method for assessing the presence or absence or the risk or degree of progression of liver disease in a subject and/or the degree of success of a procedure performed for treatment, which includes measuring the level of a biomarker in a biological sample from a subject and comparing the measured value of the biomarker with a reference value, wherein the biomarker is one or more selected from the group consisting of SEQ ID NOS: 1-125, and a program; and a data processing method for detecting liver disease at high accuracy using the liver disease noninvasive marker; and a data processing device for use in the data processing.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A sailor protection device (500), wherein a determination unit (510a) performs a determination process to determine whether a sailor is in an emergency situation, on the basis of the strength of notification radio waves received from a transmitter worn by the sailor, said transmitter repeatedly transmitting the notification radio waves, which are for providing notification of the presence of the sailor, and on the basis of detection results from a watercraft oscillation sensor that detects the intensity of oscillation of a watercraft that the sailor is aboard. When the determination unit (510a) has determined that the sailor is in an emergency situation, an on-ship output unit (510k) outputs, to an alarm apparatus, an emergency situation detection signal expressing said determination.
G08B 21/02 - Alarms for ensuring the safety of persons
G08B 25/04 - Alarm systems in which the location of the alarm condition is signalled to a central station, e.g. fire or police telegraphic systems characterised by the transmission medium using a single signalling line, e.g. in a closed loop
G08B 25/10 - Alarm systems in which the location of the alarm condition is signalled to a central station, e.g. fire or police telegraphic systems characterised by the transmission medium using wireless transmission systems
In an air bubble forming device (500) according to one embodiment of the present invention, an air bubble growth nozzle (100) has an apical end (110) thereof disposed in liquid (LQ) so as to cause an air bubble (BS) to grow at said apical end (110). A large air bubble retention member (300) retains a large air bubble (BL), which is larger than the air bubble (BS), at a position that faces the apical end (110) of the air bubble growth nozzle (100) in the liquid (LQ). The air bubble (BS) is separated from the apical end (110) of the air bubble growth nozzle (100) by an attractive force (AF) resulting from a hydrophobic interaction that takes place between the air bubble (BS) at the apical end (110) of the air bubble growth nozzle (100) and the large air bubble (BL) retained by the large air bubble retention member (300). The separated air bubble BS is released into the liquid (LQ).
B01F 23/2373 - Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media for obtaining fine bubbles, i.e. bubbles with a size below 100 µm
B01F 35/214 - Measuring characterised by the means for measuring
40.
LOW-DOSE HEPATOCYTE GROWTH FACTOR GENE THERAPY FOR DIABETES
An agent for protecting and/or regenerating pancreatic β cells in a mammal with diabetes, containing a recombinant viral vector expressing a hepatocyte growth factor (HGF), wherein the agent is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and the viral vector contains a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose is provided by the present invention.
This heat-curable composition according to the present disclosure comprises: a first component including a siloxane having an epoxy group, and a second component including at least one of: a phenol having a structure in which a ring-opening functional group (but excluding a hydroxy group), which is a functional group that has an action for opening a ring of an epoxy group, is bonded to a benzene ring; and an acyclic aliphatic compound having a structure in which the ring-opening functional group is bonded to an end thereof. The heat-curable composition production method according to the present disclosure comprises: a first component preparation step for preparing a first component including a siloxane having an epoxy group; a second component preparation step for preparing a second component including at least one of a phenol having a structure in which a ring-opening functional group (but excluding a hydroxy group), which is a functional group that has an action for opening a ring of an epoxy group, is bonded to a benzene ring, and an acyclic aliphatic compound having a structure in which the ring-opening functional group is bonded to an end thereof; and a mixing step for mixing the first component and the second component.
A granular body for lithium adsorption, which is durable and with which it is possible to efficiently utilize the ability of a lithium adsorbent, and a manufacturing method therefor are provided. This granular body for lithium adsorption contains a precursor of the lithium adsorbent and a hydrous polymer containing the precursor therein. Also, the hydrous polymer is able to form a gelatinous granular body. Due to this configuration, when the hydrous polymer has a predetermined moisture content, since the granular body is gelatinous, partial loss thereof no longer occurs and the durability of the granular body is improved. In addition, because the hydrous polymer allows a liquid such as seawater to pass, the entire lithium adsorbent can come into contact with this liquid and the ability of the lithium adsorbent can be efficiently utilized.
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
This anti-SARS-CoV-2 agent contains a compound represented by formula 1 or a salt thereof. [In formula 1, R1is a substituent having A that is a ring, and R2322, or a halogen atom].
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61P 25/00 - Drugs for disorders of the nervous system
inrr[Wm-1K-1zz[Wm-1K-1inin.Ccrr[Wm-1K-1zz[Wm-1K-1] being maintained within the range of the values to be achieved, even when the heat diffusion board is repeatedly exposed to temperatures ranging from the freezing point of water or below to the boiling point of water or above; and the values being maintained within the range to be achieved even when the heat diffusion board is exposed to a high temperature of 150°C or above.
C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
45.
METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT
A method for producing an Fc-containing molecule modifying reagent, the method comprising causing, in the presence of a base that is more basic than pyridine, a protein or a peptide to react with a cross-linking agent to form a bond between the cross-linking agent and an amino group in the peptide or the protein.
This method for hydrolyzing nylon involves monomerizing nylon using nylon hydrolase, and comprises: a step for dissolving nylon in an organic solvent in which nylon is soluble so as to prepare a nylon solution; a step for preparing a nylon precipitation liquid by adding the nylon solution to a precipitating solvent for precipitating nylon in the form of particles; a step for removing the organic solvent and the precipitating solvent from the nylon precipitation liquid; a step for adding an aqueous solution so as to prepare a nylon dispersion liquid; and a step for adding nylon hydrolase to the nylon dispersion liquid so as to hydrolyze the nylon.
C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material
C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
C08J 11/26 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing carboxylic acid groups, their anhydrides or esters
C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes
C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
C12P 13/00 - Preparation of nitrogen-containing organic compounds
This method for preparing a medical hydrogel derived from a chitosan derivative, in which aldonic acid is bonded to the amino group of the glucosamine unit of chitosan by dehydration condensation, comprises a step for performing high-pressure steam sterilization on an aqueous solution containing a chitosan derivative that has been put in a mold having a predetermined shape and obtaining a sterilized medical hydrogel having a predetermined shape. The obtained medical hydrogel can be used as a wound dressing for the treatment of wounds such as cuts, laceration, bruises, burns, and pressure sores.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells and a method for delivering a peptide vaccine specifically to the surface of specific immune cells. The peptide vaccine is combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells such as dendritic cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
METHOD FOR PRODUCING MACROPHAGES, DIFFERENTIATION INDUCING AGENT, DIFFERENTIATION INDUCTION KIT, METHOD FOR CULTURING MACROPHAGES, AGENT FOR PROMOTING MACROPHAGE PROPAGATION, KIT FOR PROMOTING MACROPHAGE PROLIFERATION, METHOD FOR MACROPHAGE PROLIFERATION, AND MACROPHAGES
This method for producing macrophages comprises a culture step for culturing hematopoietic precursor cells in the presence of a TREM2 signal activator.
This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II),
This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II),
This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II),
wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group;
or a salt thereof, or a solvate thereof.
The present invention provides a compound, a salt thereof, a solvate thereof, or a prodrug thereof; and an anti-SARS-CoV-2 drug containing the same. The compound is represented by formula (1) [where: R1, R2, and R31-61-61-6-alkoxy group, or -N(Ra)(Rb) (where Raand Rb1-101-10-alkyl group or a substituted or unsubstituted aryl group, and Raand Rbmay form a substituted or unsubstituted 5- to 7-membered ring in conjunction with an adjacent nitrogen atom); R4is -N(Ra)(Rb)(where Raand Rb1-101-10-alkyl group or a substituted or unsubstituted aryl group, and Raand Rb may form a substituted or unsubstituted 5- to 7-membered ring in conjunction with an adjacent nitrogen atom); X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom; and the hydroxyl group in the formula may be substituted with a protecting group].
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
53.
COMPOUND, SALT OF COMPOUND, ANTIBODY MODIFICATION REAGENT, METHOD FOR PRODUCING MODIFIED ANTIBODY, AND MODIFIED ANTIBODY
A compound represented by formula I or a salt thereof. (In formula I, R1represents a substituent having such a property that the pKa value of R1-H becomes 4 to 14; one of R2and R3has an IgG-binding peptide capable of binding specifically to an Fc region in IgG; and R4 represents H or a substituted or unsubstituted alkyl group having 1 to 8 carbon atoms.)
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
54.
COMPOUND, SALT OF COMPOUND, ANTIBODY MODIFICATION REAGENT, METHOD FOR PRODUCING MODIFIED ANTIBODY, AND MODIFIED ANTIBODY
A compound represented by formula I or a salt thereof. (In formula I, R1 represents a substituent having such a property that the pKa value of R1-H becomes 4 to 14; one of R2 and R3 has an IgG-binding peptide capable of binding specifically to an Fc region in IgG; and R4 represents H or a substituted or unsubstituted alkyl group having 1 to 8 carbon atoms.)
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
55.
IMAGE GENERATION PROCESSING DEVICE, THREE-DIMENSIONAL SHAPE RECONSTRUCTION SYSTEM, IMAGE GENERATION PROCESSING METHOD, AND PROGRAM
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
KAGOSHIMA UNIVERSITY (Japan)
Inventor
Kawasaki Hiroshi
Nagamatsu Genki
Iwaguchi Takafumi
Koike Kentaro
Takamatsu Jun
Abstract
This image generation processing device comprises: an intersection point set generation unit that acquires an intersection point set from the connection relationship among intersection points of laser lines detected in each frame of a video which is a group of successive frames imaged by an imaging means which is obtained by integrating and movably fixing a camera for imaging a target area during a specific period and a plurality of plane-crossing laser oscillation units for projecting plane-crossing laser beams onto a substance in the target area and from tracking results of the intersection points of the laser lines detected in the successive frames; a simultaneous equation generation unit that, on the basis of the fact that the intersection points in the intersection point set are on two laser planes formed by the plane-crossing laser beams, generates simultaneous equations by serially obtaining a plurality of constraint equations and satisfying the constraint equations simultaneously; a three-dimensional position estimation unit that reconstructs, in a projection space, three-dimensional coordinates of a laser plane by solving the simultaneous equations; and a three-dimension reconstruction unit that reconstructs, in the projection space, three-dimensional coordinates of laser line reflection positions by an optical cutting method using the estimated three-dimensional coordinates of the laser plane and the laser lines detected in each frame of the video.
G01B 11/25 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures by projecting a pattern, e.g. moiré fringes, on the object
G06T 7/55 - Depth or shape recovery from multiple images
56.
CAPSULE PRODUCTION METHOD AND CAPSULE PRODUCTION DEVICE
A cylindrical body (111) is formed in a cylindrical shape surrounding a virtual central line (VL). On an inner surface of the cylindrical body (111), a guide groove (112) having a spiral shape is formed around the virtual central line (VL). A rotation device (120) rotates the cylindrical body (111) around the virtual central line (VL). A dropping device (130) drops, onto the inner surface of the cylindrical body (111), a substance to be encapsulated and a wall material precursor liquid that is a precursor of a wall material that covers the substance to be encapsulated. The droplet dropped by the dropping device (130) rolls along the guide groove (112) of the cylindrical body (111) rotated by the rotation device (120).
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
57.
COVID-19 THERAPEUTIC AGENT AND USE OF COMPOUND FOR PRODUCING COVID-19 THERAPEUTIC AGENT
This COVID-19 therapeutic agent contains a compound selected from the group consisting of LY2090314, afuresertib, talarozole, navitoclax, and pharmaceutically acceptable salts thereof.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
An objective is to provide an Fc-modified antibody or the like having a long serum half-life according to a CCAP method, more specifically, an antibody or the like where IgBP is bound to only one site, based on findings of the inventors. Provided is an objective antibody or the like by purification and production of an Fc-modified antibody or the like with a column bound to an Fc region of an antibody. Specifically, an antibody where only one of two binding sites of Fc is selectively modified is provided by allowing an IgBP-bound antibody produced by a CCAP method to adsorb to a carrier of an IgBP-immobilized column, or forming a state where only one Fc of an antibody is bound to an IgBP binding column and then adding a peptide reagent for CCAP to the column to perform a reaction of a CCAP method in the column.
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Yamato Kenta
Miyata Takeshi
Kusakabe Takahiro
Lee Jae Man
Masuda Akitsu
Abstract
[Problem] To provide: a method for simply producing an immunogenic chrysalis for oral administration; and a chrysalis which is for oral administration and produced by said method. [Solution] This method for producing a chrysalis for oral use comprises a step for infecting a larva or chrysalis of a baculovirus infectious insect with a recombinant baculovirus, into which DNA encoding an antigen protein has been introduced, and freeze-drying a chrysalis pupated from the infected larva or the infected chrysalis.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
KAICO LTD. (Japan)
Inventor
Yamato, Kenta
Miyata, Takeshi
Kusakabe, Takahiro
Lee, Jae Man
Masuda, Akitsu
Abstract
[Problem] To provide: a method for simply producing an immunogenic chrysalis for oral administration; and a chrysalis which is for oral administration and produced by said method. [Solution] This method for producing a chrysalis for oral use comprises a step for infecting a larva or chrysalis of a baculovirus infectious insect with a recombinant baculovirus, into which DNA encoding an antigen protein has been introduced, and freeze-drying a chrysalis pupated from the infected larva or the infected chrysalis.
Provided are: an adhesive capable of achieving bonding with excellent shear strength and impact resistance; a polysiloxane composition able to be used as a component contained in this adhesive; and methods for producing the adhesive and the polysiloxane composition. This polysiloxane composition is a copolymer of: an adhesive monomer unit A comprising an organosiloxane unit having a substituent group RA2 that includes a catechol group; and a flexible monomer unit B comprising an organosiloxane unit that does not include a catechol group.
This method for manufacturing an oil extract component includes a crushing step for crushing fruit in vegetable oil, and a separation step for separating an extract oil from the mixture obtained in the crushing step. The fruit is at least one type of fruit selected from the group consisting of mandarins, mandarin hybrids, citrons, and yuzus.
This agent against a drug-resistant influenza virus contains a compound represented by formula (1), a pharmacologically acceptable salt thereof, a compound represented by formula (1) having an ester-modified, phosphoric acid-modified, or sulfuric acid-modified hydroxyl group, a compound represented by formula (1) having an ester-modified or amide-modified carboxyl group, or a compound represented by formula (1) having an imine-modified, amide-modified, or urea-modified amino group. In formula (1), X represents a hydrogen atom or a halogen atom.
The present invention provides a new gene therapy method which is less invasive and is capable of providing a desired therapeutic effect on diabetes including T1D. Specifically, provided is a pancreatic β cell protecting/regenerating formulation for mammals with diabetes, the formulation containing a nucleic acid that encodes a heparin-binding epidermal growth factor-like growth factor (HB-EGF). The formulation is characterized by being systemically administered. The above-described formulation containing, in combination, a nucleic acid that encodes a hepatocyte growth factor (HGF) is also provided.
The present invention provides a new gene therapy method which is less invasive and is capable of providing a desired therapeutic effect on diabetes including T1D. Specifically, provided is a pancreatic ß cell protecting/regenerating formulation for mammals with diabetes, the formulation containing a nucleic acid that encodes a heparin-binding epidermal growth factor-like growth factor (HB-EGF). The formulation is characterized by being systemically administered. The above-described formulation containing, in combination, a nucleic acid that encodes a hepatocyte growth factor (HGF) is also provided.
An oral cancer detection kit includes a reagent for detecting the methylation of a promoter region in each of a plurality of genes in DNA contained in a sample collected from the oral cavity of a subject. The plurality of genes includes KLLN, CASP8, CHFR and GSTP1, and whether or not the subject has oral cancer can be determined on the basis of information on methylation occurring in a promoter region which is acquired using the reagent.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12M 1/00 - Apparatus for enzymology or microbiology
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A bubble formation apparatus (500) includes: a rotor (100); a container (200) in which the rotor (100) is housed together with a liquid (LQ) and a gas (GS); and a rotary device (300) that causes rotation of the rotor (100) with the rotor (100) being pressed against an inner lower surface (221) that is the inner surface of the container (200). A bubble is formed by periodically repeating pressurization and depressurization of a mixture of the gas (GS) and the liquid (LQ) in a gap between the inner lower surface (221) and a portion, pressed against the inner lower surface (221), of the rotor (100) due to the rotation of the rotor (100) by the rotary device (300).
B01F 23/233 - Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids using driven stirrers with completely immersed stirring elements
B01F 33/452 - Magnetic mixersMixers with magnetically driven stirrers using independent floating stirring elements
B01F 27/93 - Mixers with rotary stirring devices in fixed receptaclesKneaders with stirrers rotating about a substantially vertical axis with rotary discs
B01F 27/053 - Stirrers characterised by their elements, materials or mechanical properties characterised by their materials
68.
NOVEL FINE HOLLOW PARTICLES COMPRISING MELAMINE-BASED RESIN
Each of fine hollow particles according to the present invention is composed of a resin film comprising a melamine-based resin, and is characterized in that the resin film is composed of a plurality of small-piece-like parts and binding parts that bind the small-piece-like parts to each other. According to the present invention, fine hollow particles can be provided, which have excellent solvent resistance and heat resistance, also have satisfactory dispersibility, have large grain diameters, and are stable.
C08L 61/28 - Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds with melamine
This replicon DNA includes: a CMV promoter sequence that functions in vertebrate cells; a non-structural region that is positioned on the 3' side from the CMV promoter sequence and includes non-structural protein genes 1a and 1b from SARS-CoV-2; and the N gene from SARS-CoV-2, which is positioned on the 3' side from the non-structural region.
This detection kit comprises a first carrier that supports a first probe bonding to an object being detected and that contains a first metal, and a second carrier that supports a second probe bonding to the object being detected and that contains a second metal different from the first metal. When energy is supplied to the first carrier and the second carrier that have come into proximity by bonding to the object being detected via the first probe and the second probe, intrinsic ions are desorbed.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
This invention relates to an antipruritic agent of formula (I) or (II),
This invention relates to an antipruritic agent of formula (I) or (II),
This invention relates to an antipruritic agent of formula (I) or (II),
wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group;
or a salt thereof, or a solvate thereof.
23/23/2] (1) [in formula (1), R represents a group containing a polyoxyalkylene chain] The R is preferably a group represented by formula (1−1). −R1−(OR2nn−OR3(1−1) [in formula (1−1), R1represents a single bond or a linking group; R2represents an alkylene group having 2 to 8 carbon atoms; R3 represents a hydrocarbon group having 1 to 4 carbon atoms; n represents an integer of 2 to 30; and a bond hand extending from the left side of the formula binds to a silicon atom in formula (1).]
C08G 79/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon
73.
LOW-DOSE HEPATOCYTE GROWTH FACTOR GENE THERAPY FOR DIABETES
The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent is characterized by being administered in a dose of 1010-1012 virus particles (vp)/kg body weight, and by the virus vector including a nucleic acid that encodes HGF downstream of a promoter having transcription activity capable of yielding a therapeutically effective HGF level in the blood at said dose.
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japan)
KAGOSHIMA UNIVERSITY (Japan)
NAGASAKI UNIVERSITY (Japan)
Inventor
Kohara, Michinori
Yasui, Fumihiko
Yamane, Daisuke
Kohara, Kyoko
Morita, Kouichi
Yasutomi, Yasuhiro
Ishii, Koji
Abstract
The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 49/16 - Saturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
C07K 1/10 - General processes for the preparation of peptides using coupling agents
C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C07C 49/16 - Saturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
C07K 1/10 - General processes for the preparation of peptides using coupling agents
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
The present invention provides a new use of 1,5-anhydrofructose and 1,5-anhydroglucitol that is a metabolic product of 1,5-anhydrofructose. The present invention pertains to a composition for improving renal function, said composition comprising 1,5-anhydrofructose and/or 1,5-anhydroglucitol as an active ingredient.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
78.
IMMORTALIZED PORCINE ALVEOLAR MACROPHAGE CULTURED CELL LINE, METHOD FOR PRODUCING IMMORTALIZED PORCINE ALVEOLAR MACROPHAGE CULTURED CELL LINE, REAGENT FOR PREPARING IMMORTALIZED PORCINE ALVEOLAR MACROPHAGE CULTURED CELL LINE, AND METHOD FOR PRODUCING VACCINE
This immortalized porcine alveolar macrophage cultured cell line has a viral long terminal repeat, expresses a gene that induces cell immortalization, and is sensitive to porcine reproductive and respiratory syndrome virus and/or African swine fever virus.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KAGOSHIMA UNIVERSITY (Japan)
SHOWA UNIVERSITY (Japan)
Inventor
Takasaki Ichiro
Toyooka Naoki
Okada Takuya
Kurihara Takashi
Gouda Hiroaki
Abstract
The present invention pertains to: a compound represented by formula (I) (in the formula, R11-61-61-61-61-6-alkyl amino group, R21-61-61-61-61-6-alkyl amino group, R31-61-61-6-alkyl group, and R43-123-12-hydrocarbon group) or a salt thereof, or a solvate thereof; and an analgesic drug that contains the compound or a salt thereof, or a solvate thereof.
C07D 239/91 - Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Provided is a novel remedy for inflammatory diseases or a novel suppressant against the production of inflammatory cytokines. The present invention is a remedy for inflammatory diseases or a suppressant against the production of inflammatory cytokines that contains, as an active ingredient, a substance that directly or indirectly inhibits interaction between damage-associated molecular patterns (DAMPs) and receptors therefor. According to this remedy for inflammatory diseases or suppressant against the production of inflammatory cytokines, the expression of inflammatory cytokines such as TNFα, IL-6, and IL-8 is suppressed due to the substance that serves as the active ingredient bonding to MD-2 and/or any selected from among nucleophosmin (NPM), histone H2A, histone H2B, histone H3, and histone H4 and inhibiting transmission of signals mediated by MD-2/TLR4 of DAMPs.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The purpose of the present invention is to provide a solid-phase carrier on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after IgG purification, and having a high binding affinity for IgG. Specifically, the present invention relates to a solid-phase carrier on which an IgG-binding peptide is immobilized, wherein the two cysteine residues on the outside of the peptide are linked as shown in the following formula:
(in the formula, the upper cysteine residue is on the N-terminal side of the peptide, and the lower cysteine residue is on the C-terminal side of the peptide).
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
B01D 15/10 - Selective adsorption, e.g. chromatography characterised by constructional or operational features
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
The present invention pertains to an anti-SARS-CoV-2 drug containing a compound represented by formula (I): [in the formula, one of Raand Rcis a substituted phenylamino group, the other of Raand Rc1-101-10-alkyl group, Rb, Rf, and Rgare the same or different and are hydrogen atoms or deuterium atoms, Rdis a hydrogen atom, a deuterium atom, or a chlorine atom, and Re is a hydrogen atom, a deuterium atom, or a halogen atom] or a salt thereof, or a solvate of these.
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
OSAKA UNIVERSITY (Japan)
Inventor
Kurihara Takashi
Takasaki Ichiro
Hashimoto Hitoshi
Hayata Atsuko
Shintani Yusuke
Abstract
The present invention relates to an antidepressant/anxiolytic drug containing a compound represented by formula (I) or (II): (in the formulas, R11-61-62-61-61-61-6-haloalkoxy group, or an optionally substituted phenyl group; R21-61-62-61-61-61-6-haloalkoxy group, or an optionally substituted phenyl group; an R is an indazolyl group substituted by a halogen atom, an optionally substituted phenyl group, a pyrazolyl group, or an optionally substituted aralkyl group), or a salt thereof, or a solvate of these.
The present invention addresses the problem of providing a peptide vaccine in which a peptide vaccine has been complexed so as to enable specific delivery to the surface of a prescribed immune cell. The present invention also addresses the problem of providing a method for specifically delivering a peptide vaccine to the surface of a prescribed immune cell. As a result of intensive investigations, the inventors of the present invention demonstrated that these problems can be solved by providing a peptide vaccine that has been combined with an IgG-binding peptide and can bind with an IgG that characteristically is an agonist for a molecule on the surface of a prescribed immune cell (for example, dendritic cells).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
F02K 9/72 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant thereforControl thereof using liquid and solid propellants, i.e. hybrid rocket-engine plants
F02K 9/12 - Shape or structure of solid propellant charges made of two or more portions burning at different rates
F02K 9/50 - Feeding propellants using pressurised fluid to pressurize the propellants
B64G 1/40 - Arrangements or adaptations of propulsion systems
F02K 9/60 - Constructional partsDetails not otherwise provided for
87.
Antibody binding to chondroitin sulfate proteoglycan 5
The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II),
2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
90.
IgG-binding peptide, and specific modification of antibody with said peptide
It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.
The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The purpose of the present invention is to provide an Fc-modified antibody which has a long half-life in the blood and is obtained through a CCAP method. More specifically, the purpose of the present invention is to provide an antibody in which IgBP is bound to only one site, on the basis of the findings found by the present inventors. The present invention provides a target antibody or the like by purifying and producing an Fc-modified antibody or the like using a column that binds to an Fc region of an antibody. Specifically, the present invention provides an antibody in which only one site among two binding sites of Fc is selectively modified by adsorbing an IgBP-binding antibody produced through the CCAP method on a carrier of a IgBP-immobilized column, or by adding, in a state where only one Fc of the antibody is bound to an IgBP-binding column, a peptide reagent for CCAP to the column and performing the reaction of the CCAP method in the column.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
An objective is to provide an Fc-modified antibody or the like having a long serum half-life according to a CCAP method, more specifically, an antibody or the like where IgBP is bound to only one site, based on findings of the inventors. Provided is an objective antibody or the like by purification and production of an Fc-modified antibody or the like with a column bound to an Fc region of an antibody. Specifically, an antibody where only one of two binding sites of Fc is selectively modified is provided by allowing an IgBP-bound antibody produced by a CCAP method to adsorb to a carrier of an IgBP-immobilized column, or forming a state where only one Fc of an antibody is bound to an IgBP binding column and then adding a peptide reagent for CCAP to the column to perform a reaction of a CCAP method in the column.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
94.
INFORMATION PROCESSING DEVICE, IDENTIFYING METHOD, AND IDENTIFYING PROGRAM
An information processing device (100) includes: an acquiring unit (120) for acquiring inspection result information (111) indicating a plurality of degrees of damage corresponding to a plurality of deformations of each of a plurality of parts of a civil engineering structure inspected in the past, and a plurality of in-service periods corresponding to the plurality of parts, and maintenance determination information (112) indicating whether maintenance is to be performed, in accordance with a combination of the respective degrees of damage of the plurality of deformations; a generating unit (140) for generating predicted information indicating the degree of damage in a future in-service period, for each of the plurality of deformations, using information for deriving the degree of damage in a future in-service period for each of the plurality of deformations, obtained on the basis of the inspection result information (111); and an identifying unit (150) for identifying the maintenance timing on the basis of the maintenance determination information (112) and the predicted information.
An information processing device (100) has: an acquisition unit (120) that acquires inspection results information (111) indicating multiple degrees of damage corresponding to multiple deformities in each of a plurality of sections of a civil engineering structure previously inspected and multiple service periods corresponding to the plurality of sections, and repair determination information (112) indicating whether to carry out repairs depending on the combinations of each of the multiple degrees of damage for the multiple deformities; a generation unit (140) that generates prediction information indicating the degree of damage for a future service period in each of the multiple deformities using information acquired on the basis of the inspection results information (111) and used for deducing the degree of damage during a future service period for each of the multiple deformities; and a specification unit (150) that specifies the timing for repairs on the basis of the repair determination information (112) and the prediction information.
E01C 23/00 - Auxiliary devices or arrangements for constructing, repairing, reconditioning, or taking-up road or like surfaces
E01D 22/00 - Methods or apparatus for repairing or strengthening existing bridges
96.
Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene
The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
[Problem] The objective of the invention is, instead of trapping and combining oil droplets, to use an oil film to promote the coalescence of the oil droplets so that pressure losses can be reduced and mesh clogging can be suppressed. [Solution] The coalescer 11 is installed in a flow path through which flows a liquid to be processed in which oil droplets are mixed. Metal meshes 12, each assuming a sheet shape and having been plain-woven, twill-woven, thickly woven, or the like, are layered to form mesh layers 16 and interlayer sections 15 therebetween. The direction of the surfaces of the metal meshes 12 is oriented in the same direction as the direction of flow of the liquid to be processed. Concomitantly to the flow of the liquid to be processed, oil droplets 31 that have entered into contact with a weft material 13, a warp material 14 or both, are turned into an oil film 32 which is made to flow down and grown into a macrodrop particle 34 at the downward end of the mesh layer, and the macrodrop particle 34 is separated from the coalescer 11 by following the flow of the liquid to be processed.
A bubble formation device (500) comprises a rotor (100), a container (200) in which the rotor (100) is accommodated along with a liquid (LQ) and a gas (GS), and a rotation device (300) that causes the rotor (100) to rotate in a state in which the rotor (100) is pressed against an inner bottom face (221) that is an inner face of the container (200). Bubbles are formed by way of periodically repeating pressurizing and depressurizing a mixture of the gas (GS) and the liquid (LQ) in the gap between the portion of the rotor (100) pressed against the inner bottom face (221) and the inner bottom face (221) due to the rotation of the rotor (100) by the rotation device (300).
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Miyata Takeshi
Kurihara Koichi
Sato Keita
Kamiya Noriho
Minamihata Kosuke
Kusakabe Takahiro
Abstract
Disclosed is a method for producing a polymerized polypeptide aggregate, said method comprising a step for reacting a polypeptide, which has a tag on the N-terminal side and/or C-terminal side, with a polymerase to give a reaction liquid containing a polymerized polypeptide; a step for freezing the reaction liquid; and a step for thawing the frozen reaction liquid, wherein the polymerase recognizes the tag.
The present invention addresses the problem of providing: a nucleic acid analog; and a pharmaceutical composition, an anti-hepatitis virus agent and a hepatitis virus-related disease preventing or treating agent, each containing a nucleic acid analog as an active ingredient. Said problem can be solved by a compound represented by (1) (in the formula, Z is bromine or iodine), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
patents
